Treatment with AC pulsed electromagnetic fields improves the response to levodopa in Parkinson's disease

International Journal of Neuroscience

Volumn 91, Issue 3-4, 1997, Pages 189-197

  Sandyk, Reuven ^a,b  

^a TOURO COLLEGE   (United States)

^b NONE   (United States)

Author keywords

Dopamine; Drug efficacy; Electromagnetic fields; End of dose deterioration; Levodopa; Parkinson's disease; Pineal gland; Serotonin

Indexed keywords

EID: 0031259629     PISSN: 00207454     EISSN: None     Source Type: Journal    
DOI: 10.3109/00207459708986376     Document Type: Article

References (53)

1. Antolin, I., Rodriguez, C , Sainz, R. M., Mayo, J., Uria, H., Kotler, M. L., Rodriguez-Colunga, M. J., Tolivia, D. & Menedez-Pelaez, A. (1996). "Neurohormone melatonin prevents cell damage: effect on gene expression for antioxidant enzymes," FASEB Journal, 10, 882-890.
2. Bawin, S. M. & Adey, W. R. (1976). "Sensitivity of calcium binding in cerebral tissue to weak environmental electric fields oscillating at low frequency," Proceedings of the National Academy of Sciences, USA, 73, 1999-2003
3. Barlow-Walden, L. R., Reiter, R. J., Abe, M., Pablos, M., Menendez-Pelaez, A., Chen, L. D. & Poeggeler, B (1995). "Melatonin stimulates brain glutathione peroxidase activity," Neurochemistry International, 26, 497-502.
4. Bernheimer, H., Birkmayer, W. & Homykiewicz, O. (1961). "Verteilung des 5-hydroxytryptamins (Serotonin) in Gehirn des Menschen und sein Verhalten bein Patienten mit Parkinson Syndrome," Klinische Wochenschrift. 39, 1056-1059.
5. Blackman, C. F. (1988). Stimulation of brain tissue in vitro by extremely low frequency, low intensity, sinusoidal electromagnetic fields. In M. E. O'connor & R. H. Lovely (eds.), Electromagnetic fields and neurobehavioral function. (Alan R. Liss, New York.)
6. Bradbury, A J., Kelly, M. E. & Smith, J. A. (1985) Melatonin "Melatonin action in the mid-brain can regulate dopamine function both behaviourally and biochemically. In G.M. Brown & S.D. Wainwright (eds ), The pineal gland: endocrine aspects, pp. 327-332. (Pergamon Press, Oxford.)
7. Cotzias, G. C., Tang, L. C., Miller, S. T. & Ginos, J. Z. (1971). "Melatonin and abnormal movement induced by L-dopa in mice," Science, 173, 450-452.
8. Davidson, D. L. W., Yates, C. M , Mawdsley, C., Pullar, I. A. & Wilson, H. (1977). "CSF studies on the relationship between dopamine and 5-hydroxytryptamine in Parkinsonism and other movement disorders," Journal of Neurology Neurosurgery and Psychiatry, 40, 1136-1141.
9. Dray, A. (1981). "Serotonin in the basal ganglia: functions and interactions with other neuronal pathways," Journal of Physiology, (Paris), 77, 393-103.
10. Ehringer, H. & Homykiewicz, O. (1960). "Verteilung von Noradrenalin und Dopamine (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalar Systems," Wien Klinischer Wochenschrift, 38, 1236-1239.
11. Fahn, S. (1981) Fluctuations of disability in Parkinson's s disease: pathophysiological aspects. In C.D. Marsden & S. Fahn (eds.), Movement disorders, pp. 123-145 (Butterworths Scientific, London.)
12. Fahn, S & Cohen, G. (1992). "The oxidant stress hypothesis in Parkinson's disease: evidence supporting it," Annals of Neurology, 32, 804-812.
13. Fahn, S., Libsch, L. R. & Cutler, R. W. (1971), "Monoamines in the human neostriatum: Topographic distribution in normals in Parkinson's disease and their role in akinesia, rigidity, chorea and tremor," Journal of Neurological Sciences, 14, 427-455.
14. Gancher, S. T. & Nutt, J. G. (1987). "Diurnal responsiveness to apomorphine," Neurology, 37, 1250-1253.
15. Gershanik, O. S., Heikkila, R E. & Duvoisin, R. C. (1979). "The role of serotonin neurons in the action of L-dopa in an animal model of Parkinsonism," Neurology, 29(suppl), 553.
16. Giusti, P., Gusella, M., Lipartiti, M., Milani, D., Zhu, W., Vicini, S & Manev, H. (1995), "Melatonin protects primary cultures of cerebellar granule neurons from kainate but not from N-Methyl-D-Aspartate excitotoxicity," Experimental Neurology, 131, 39-46.
17. Hoehn, M. M. & Yahr, M. D. (1967). "Parkinsonism: onset, progression, and mortality," Neurology, 17, 427-442
18. Jaffe, R. A., Laszewski, B. L., Carr, D. B. & Phillips, R. D. (1980). "Chronic exposure to a 60-Hz electric field: effects on synaptic transmission and peripheral nerve function in the rat," Bioelectromagnetics, 1, 131-147.
19. Jolley, W B., Hinshaw, D B., Knierim, K. & Hinshaw, D. B (1983). "Magnetic field effects on calcium efflux and insulin secretion in isolated rabbit iselts of langerhans," Bioelectromagnetics, 4, 103-106.
20. Kaczmarek, L. & Adey, W. (1974). "Weak electric gradient change ionic and transmitter fluxes in cortex," Brain Research, 66, 537-540.
21. Karabakhtsian, R., Broude, N., Shalts, N., Kochlatyi, S., Goodman, R. & Henderson, A. S. (1994). "Calcium is necessary in the cell response to EM fields," FEBS Letters, 349, 1-6.
22. Manev, H., Uz, T., Kharlamov, A. & Joo, J. Y. (1996). "Increased brain damage after stroke or excitotoxic seizures in melatonin-deficient rats," FASEB Journal, 10, 1546-1551.
23. Marsden, C. D. & Parkes, J. D (1976), "On-off effects in patients with Parkinson's disease on chronic levodopa therapy," Lancet, 1, 292-296.
24. Marsden, C. D. & Parkes, J. D. (1980). "On and off" variability and response swings in Parkinson's disease. In F. C. Rose & R. Capildeo (eds.), Research progress in parkinson's disease, pp 265-274, (Pitman Medical, Kent).
25. Marsden, C. D., Parkes, J. & Quinn, N. (1981). Fluctuations of disability in Parkinson's disease: clinical aspects. In C.D. Marsden & S. Fahn (eds.), Movement disorders, pp. 96-122, (Butterworths Scientific, London).
26. Meara, J. (1996). "Serotonin and the extrapyramidal system- a neurological perspective," Human Psychopharmacology, 11, S95-S102.
27. Miguez, J. M , Martin, F. & Aldegunde, M (1991). "Long-term pinealectomy alters hypothalamic serotonin metabolism in the rat," Journal of Pineal Research, 11, 75-79.
28. Miguez, J. M., Martin, F. J. & Aldegunde, M. (1994). "Effects of single doses and daily melatonin treatments on serotonin metabolism in rat brain regions," Journal of Pineal Research, 17, 170-376.
29. Nausieda, P., Weiner, W. J., Kaplan, L. R., Weber, S. & Klawans, H. L (1982). "sleep disruption in the course of levodopa therapy: an early feature of the levodopa psychosis," Clinical Neuropharmacology, 5, 183-194.
30. Nausieda, P., Glantz, R., Weber, S , Baum, R. & Klawans, H. L. (1984). Psychiatric complications of levodopa therapy of Parkinson's disease. In R G Hassler & J.F. Christ (eds.), Advances in neurology, vol. 40, pp. 271-277, (Raven Press, New York).
31. Olanow, C W. (1996). "A 61-year-old man with Parkinson's disease," Journal of the American Medical Association, 275, 716-722.
32. Reiter, R. J (1995), "Oxidative processes and antioxidative defense mechanism in the aging brain," FASEB Journal, 9, 526-533.
33. Riederer, P (1980). "L-dopa competes with tyrosine and tryptophan for human brain uptake," Nutrition & Metabolism, 24, 417-423.
34. Rosen, A. D (1992). "Magnetic field influence on acetylcholine release at the neuromuscular junction," Amarican Journal of Physiology, 262, C1418-C1422.
35. Rudolph, K., Wirz-Justice, A., Krauchi, K. & Feer, H. (1988) "Static magnetic fields decrease nocturnal pineal cAMP in the rat," Brain Research, 446, 159-160.
36. Sandyk, R. (1992 a). "Weak magnetic fields as a novel therapeutic modality in Parkinson's disease," International Journal of Neuroscience, 66, 1-15.
37. Sandyk, R. (1992 b). "Weak magnetic fields in the treatment of Parkinson's disease with the "on-off" phenomenon," International Journal of Neuroscience, 66, 97-106.
38. Sandyk, R. (1992 c). "Magnetic fields in the therapy of Parkinsonism," International Journal of Neuroscience, 66, 209-235.
39. Sandyk, R. (1994 a). "A drug naive Parkinsonian patient successfully treated with electromagnetic fields," International Journal of Neuroscience, 79, 99-110.
40. Sandyk, R. (1994 a). "Treatment of Parkinson's disease with magnetic fields reduces the requirement for antiparkmsonian medications," International Journal of Neuroscience, 74, 191-201.
41. Sandyk, R. (1996). "Freezing of gait in Parkinson's disease is improved by treatment with weak electromagnetic fields," International Journal of Neuroscience, 85, 111-124.
42. Sandyk, R. & Derpapas, K. (1993 a). "The effects of external picotesla range magnetic fields on the EEG in Parkinson's disease," International Journal of Neuroscience, 70, 85-96.
43. Sandyk, R & Derpapas, K. (1993 b). "Further observations on the unique efficacy of picotesla magnetic fields in Parkinson's disease," International Journal of Neuroscience, 69, 167-183.
44. Sawada, M., Nagatsu, T., Nagtsu, I., Ito, K., Lizuka, R., Kondo, T. & Narabayashi, H (1985). "Tryptophan hydroxylase activity in the brains of controls and Parkinsonian patients," Journal of Neural Transmission, 62, 107-115.
45. Scatton, B., Javoy-Agid, F., Rouquier, L., Dubois, B. & Agid, Y. (1983) "Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson,s disease," Brain Research, 275, 321-328.
46. Scatton, B., Dennis, T., L'heureux, R., Monfort, J. C., Duyckaerts, C. & Javoy-Agid, F. (1986). "Degeneration of noradrenergic and serotonergic but not dopaminergic neurones in the lumbar spinal cord of parkinsonian patients," Brain Research, 380, 181-185
47. Semm, P. (1992). Pineal function in mammals and birds is altered by earth-strength magnetic fields. In M.C. Moore-Ede, S.S. Campbell & R.J. Reiter (eds.), Electromagnetic fields and circadian rhythmicity, pp 53-62, (Birkhauser, Boston.)
48. Semm, P., Schneider, T. & Vollrath, L. (1980). "Effects of an earth-strength magnetic field on electrical activity of pineal cells," Nature, 288, 607-608.
49. Tohgi, H., Abe, T., Takahashi, S., Takahashi, J. & Hamato, H. (1993). "Alteration in the concentration of serotonergic and dopaminergic substances in the cerebrospmal fluid of patients with Parkinson,s disease, and their changes after L-dopa administration," Neuroscience Letters, 159, 135-138
50. Trabulsi, R., Pawlowski, B. & Wieraszko, A. (1996). "The influence of steady magnetic fields on the mouse hippocampal evoked potentials in vitro," Brain Research, 728, 135-139.
51. Walleczek, J. (1992). "Electromagnetic field effect on cells of the immune system: the role of calcium signalline," FASEB Journal, 6, 3177-3185.
52. Welker, H. A., Semm, P., Willig, R. P., Commetz, J. C., Wiltschko, W. & Vollrath, L. (1983). "Effects of an artificial magnetic field on serotonin N-acetyltransferase activity and melatonin content of the rat pineal gland," Experimental Brain Research, 50, 426-432.
53. Wilson, B. W., Stevens, R. G. & Anderson, L. E. (1989). "Neuroendocrine mediated effects of electromagnetic field exposure possible role of the pineal gland," Life Sciences, 45, 1319-1332.